First-In-Human Administration of Allogeneic Amnion Cells in Premature Infants With Bronchopulmonary Dysplasia: A Safety Study

Rebecca Lim, Atul Malhotra, Jean Tan, Siow Teng Chan, Sinnee Lau, Dandan Zhu, Joanne C. Mockler, Euan M. Wallace

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Bronchopulmonary dysplasia (BPD) is a chronic lung disease that mainly affects premature babies who require ventilator support. The pathogenesis of BPD is complex but includes vascular maldevelopment, alveolarization arrest, and lung inflammation. There is no cure for BPD. Clinical care is limited to supportive respiratory measures. A population of stem-like cells derived from placental membranes, human amnion epithelial cells (hAECs), has shown therapeutic promise in preclinical models of BPD. With a view to future efficacy trials, we undertook a first-in-human clinical trial of hAECs in babies with BPD to assess the safety of these cells. In a single-center, open-label phase I trial, we administered allogeneic hAECs (1 × 106 per kilogram bodyweight) by intravenous infusion to six premature babies with BPD. The primary outcomes of the study were focused on safety, including local site reaction, anaphylaxis, infection, features of rejection, or tumor formation. Outcomes to discharge from neonatal unit were studied. The hAECs were well tolerated. In the first baby, there was transient cardiorespiratory compromise during cell administration consistent with a pulmonary embolic event. Following changes to cell administration methods, including introduction of an inline filter, and reducing the cell concentration and the rate of cell infusion, no such events were observed in the subsequent five babies. We did not see evidence of any other adverse events related to cell administration. Allogeneic hAECs can be safely infused into babies with established BPD. Future randomized clinical trials to assess efficacy in this patient population are justified. Stem Cells Translational Medicine 2018;7:628–635.

Original languageEnglish
Pages (from-to)628-635
Number of pages8
JournalStem Cells Translational Medicine
Volume7
Issue number9
DOIs
Publication statusPublished - 1 Sep 2018

Keywords

  • Adult stem cells
  • Cell transplantation
  • Cellular therapy
  • Clinical translation
  • Clinical trials
  • Lung
  • Placenta

Cite this

@article{e690e9144969466bb14d0c366c06a552,
title = "First-In-Human Administration of Allogeneic Amnion Cells in Premature Infants With Bronchopulmonary Dysplasia: A Safety Study",
abstract = "Bronchopulmonary dysplasia (BPD) is a chronic lung disease that mainly affects premature babies who require ventilator support. The pathogenesis of BPD is complex but includes vascular maldevelopment, alveolarization arrest, and lung inflammation. There is no cure for BPD. Clinical care is limited to supportive respiratory measures. A population of stem-like cells derived from placental membranes, human amnion epithelial cells (hAECs), has shown therapeutic promise in preclinical models of BPD. With a view to future efficacy trials, we undertook a first-in-human clinical trial of hAECs in babies with BPD to assess the safety of these cells. In a single-center, open-label phase I trial, we administered allogeneic hAECs (1 × 106 per kilogram bodyweight) by intravenous infusion to six premature babies with BPD. The primary outcomes of the study were focused on safety, including local site reaction, anaphylaxis, infection, features of rejection, or tumor formation. Outcomes to discharge from neonatal unit were studied. The hAECs were well tolerated. In the first baby, there was transient cardiorespiratory compromise during cell administration consistent with a pulmonary embolic event. Following changes to cell administration methods, including introduction of an inline filter, and reducing the cell concentration and the rate of cell infusion, no such events were observed in the subsequent five babies. We did not see evidence of any other adverse events related to cell administration. Allogeneic hAECs can be safely infused into babies with established BPD. Future randomized clinical trials to assess efficacy in this patient population are justified. Stem Cells Translational Medicine 2018;7:628–635.",
keywords = "Adult stem cells, Cell transplantation, Cellular therapy, Clinical translation, Clinical trials, Lung, Placenta",
author = "Rebecca Lim and Atul Malhotra and Jean Tan and Chan, {Siow Teng} and Sinnee Lau and Dandan Zhu and Mockler, {Joanne C.} and Wallace, {Euan M.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1002/sctm.18-0079",
language = "English",
volume = "7",
pages = "628--635",
journal = "Stem Cells Translational Medicine",
issn = "2157-6564",
publisher = "Alphamed Press",
number = "9",

}

First-In-Human Administration of Allogeneic Amnion Cells in Premature Infants With Bronchopulmonary Dysplasia : A Safety Study. / Lim, Rebecca; Malhotra, Atul; Tan, Jean; Chan, Siow Teng; Lau, Sinnee; Zhu, Dandan; Mockler, Joanne C.; Wallace, Euan M.

In: Stem Cells Translational Medicine, Vol. 7, No. 9, 01.09.2018, p. 628-635.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - First-In-Human Administration of Allogeneic Amnion Cells in Premature Infants With Bronchopulmonary Dysplasia

T2 - A Safety Study

AU - Lim, Rebecca

AU - Malhotra, Atul

AU - Tan, Jean

AU - Chan, Siow Teng

AU - Lau, Sinnee

AU - Zhu, Dandan

AU - Mockler, Joanne C.

AU - Wallace, Euan M.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Bronchopulmonary dysplasia (BPD) is a chronic lung disease that mainly affects premature babies who require ventilator support. The pathogenesis of BPD is complex but includes vascular maldevelopment, alveolarization arrest, and lung inflammation. There is no cure for BPD. Clinical care is limited to supportive respiratory measures. A population of stem-like cells derived from placental membranes, human amnion epithelial cells (hAECs), has shown therapeutic promise in preclinical models of BPD. With a view to future efficacy trials, we undertook a first-in-human clinical trial of hAECs in babies with BPD to assess the safety of these cells. In a single-center, open-label phase I trial, we administered allogeneic hAECs (1 × 106 per kilogram bodyweight) by intravenous infusion to six premature babies with BPD. The primary outcomes of the study were focused on safety, including local site reaction, anaphylaxis, infection, features of rejection, or tumor formation. Outcomes to discharge from neonatal unit were studied. The hAECs were well tolerated. In the first baby, there was transient cardiorespiratory compromise during cell administration consistent with a pulmonary embolic event. Following changes to cell administration methods, including introduction of an inline filter, and reducing the cell concentration and the rate of cell infusion, no such events were observed in the subsequent five babies. We did not see evidence of any other adverse events related to cell administration. Allogeneic hAECs can be safely infused into babies with established BPD. Future randomized clinical trials to assess efficacy in this patient population are justified. Stem Cells Translational Medicine 2018;7:628–635.

AB - Bronchopulmonary dysplasia (BPD) is a chronic lung disease that mainly affects premature babies who require ventilator support. The pathogenesis of BPD is complex but includes vascular maldevelopment, alveolarization arrest, and lung inflammation. There is no cure for BPD. Clinical care is limited to supportive respiratory measures. A population of stem-like cells derived from placental membranes, human amnion epithelial cells (hAECs), has shown therapeutic promise in preclinical models of BPD. With a view to future efficacy trials, we undertook a first-in-human clinical trial of hAECs in babies with BPD to assess the safety of these cells. In a single-center, open-label phase I trial, we administered allogeneic hAECs (1 × 106 per kilogram bodyweight) by intravenous infusion to six premature babies with BPD. The primary outcomes of the study were focused on safety, including local site reaction, anaphylaxis, infection, features of rejection, or tumor formation. Outcomes to discharge from neonatal unit were studied. The hAECs were well tolerated. In the first baby, there was transient cardiorespiratory compromise during cell administration consistent with a pulmonary embolic event. Following changes to cell administration methods, including introduction of an inline filter, and reducing the cell concentration and the rate of cell infusion, no such events were observed in the subsequent five babies. We did not see evidence of any other adverse events related to cell administration. Allogeneic hAECs can be safely infused into babies with established BPD. Future randomized clinical trials to assess efficacy in this patient population are justified. Stem Cells Translational Medicine 2018;7:628–635.

KW - Adult stem cells

KW - Cell transplantation

KW - Cellular therapy

KW - Clinical translation

KW - Clinical trials

KW - Lung

KW - Placenta

UR - http://www.scopus.com/inward/record.url?scp=85052810746&partnerID=8YFLogxK

U2 - 10.1002/sctm.18-0079

DO - 10.1002/sctm.18-0079

M3 - Article

VL - 7

SP - 628

EP - 635

JO - Stem Cells Translational Medicine

JF - Stem Cells Translational Medicine

SN - 2157-6564

IS - 9

ER -